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Since antisera to rat and mouse ax-foetoprotein
(AFP) are found to induce cytotoxic effects on
AFP-producing rat or mouse hepatocellular
carcinoma cells in vitro and in vivo (Tsukada et al.,
1974a; Mizejewski & Allen, 1974) further analysis
of this phenomenon was undertaken. The
observation of AFP on the cell surface of AFP-
producing hepatoma cells by the membrane
immunofluoresence technique is clearly indicative of
the formation of AFP: anti AFP antibody
complexes on the plasma membrane (Tsukada et
al., 1974a; Mizejewski & Allen, 1978).
In in vitro and in vivo studies, selective decrease
of high AFP-producing cells as well as insufficient
uptake of energy sources are observed when AFP-
producing rat hepatoma cells were treated with
anti-AFP antibodies (Tsukada et al., 1974b; Wepsic
et al., 1980; Ohkawa et al., 1984). Affinity-purified
antibodies to AFP fully retained their cytotoxic
activities (Hirai et al., 1984).
Recently, in order to increase the cytotoxic effect
of anti-AFP antibody on the tumour target cells,
we have successfully developed specific targeting
chemotherapy using anti-AFP antibody with which
daunorubicin (DM) was conjugated via periodate-
oxidized dextran (Tsukada et al., 1982a, 1982b,
1983).
Further, we have developed a new method of
conjugating DM with antibody using a novel thiol
derivative of poly-L-glutamic acid (PLGA) as the
intermediate drug carrier (Tsukada et al., 1984;
Kato et al., 1984). The functional thiol group is
used for binding DM-linked PLGA with antibody.
With the assurance of binding of the intermediary
(PLGA) molecule at only one site to the antibody
molecule, this method avoids the formation of
high-molecular-weight and aggregated material
often encountered in previous methods with
intermediaries.
In the present study, using this new method we
made a PLGA-mediated DM conjugate with
antibody to human AFP (aAFP) (aAFP-PLGA-
DM) and evaluated the growth-inhibitory effect of
the conjugate on a human AFP-producing tumour
growing in nude mice.
Horse antiserum was produced by 4s.c. weekly
immunisations with lmg of purified human AFP
emulsified in Freund's complete adjuvant. aAFP
was purified from the antiserum by affinity chroma-
tography on Sepharose 4B coupled to human AFP
(Hirai et al., 1981, Nishi & Hirai, 1972).
The high AFP-producing human hepatocellular
carcinoma Li-7 was maintained by serial passage in
athymic BALB/c nude mice (Hirohashi et al.,
1979). The Li-7 tumour grows as well-vascularized
soft masses whose volume is expressed as
V=[major diamater (mm)] x [minor diameter
(MM)]2/2 (Ovejera, et al., 1978).
In the test and control conjugates, DM was
linked via PLGA to aAFP and normal horse im-
munoglobulin (nlg), respectively.
These conjugates, abbreviated as aAFP-PLGA-
DM and nIg-PLGA-DM, were prepared with the
use of an appropriate Ig by the method detailed
previously (Tsukada et al., 1984). Briefly, for the
preparation of PLGA having a single thiol group at
its N-terminal (HS-PLGA), the masked thiol, 2-
pyridyldithio group was introduced to the N-
terminal of PLGA (average mol. wt., 17,000 as Na
salt; Sigma Chemical Co., St Louis, Mo., USA) by
the action of N-succinimidyl 3-(2-pyridyldithio)pro-
pionate (SPDP; Pharmacia Chemicals AB, Uppsala,
Sweden), and the free thiol group was generated
from the masked form with dithiothreitol (DTT).
HS-PLGA free from unreacted PLGA was isolated
by affinity chromatography by the use of
thiopropyl sepharose 6B resin. The thiol group of
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the purified HS-PLGA was protected as the 2-
pyridyldithio group by the action of 2-pyridyldi-
sulfide, and DM was linked to the PLGA derivative
(Py-ss-PLGA) with the aid of l-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide (Py-ss-PLGA-DM). The
thiol group-reactive maleimide group was introduced
to Ig with N-succinimidyl 4-(N-maleimido)butyrate,
and the resulting modified Ig was treated with the
DM-linked HS-PLGA (HS-PLGA-DM) whose thiol
group had been regenerated from Py-ss-PLGA-DM
with DTT. The conjugates thus formed were
purified by large-scale disc polyacrylamide gel
electrophoresis.
For the experiment, 0.1ml of the Li-7 tumour
mince (- 1-1.5 x 106 viable cells) was transplanted
s.c. into nude mice on day 0. The mice were treated
with an i.p. injection of the conjugate or other test
material twice a week starting from day 17 for a
total of 8 doses. One dose of the conjugate per
mouse included 10pg DM and 142pg aAFP. Other
test materials were aAFP, DM, a mixture of the
two (aAFP plus DM), DM-linked PLGA (PLGA-
DM), a mixture of aAFP and PLGA-DM (aAFP
plus PLGA-GM) and nlg-PLGA-DM. PBS served
as the control. These materials were given at doses
corresponding to those of the conjugate. Each
group consisted of 5 nude mice. For assessment of
the therapeutic or toxic effect, the growth of tumour
and body weight were measured at every injection
time. The growth rate of the tumour at every
measurement time was expressed as the relative
tumour size (RTS) which was the tumour volume
on a particular day divided by the tumour volume
on day 17. On day 49 all the mice were killed
by cervical dislocation and serum AFP levels were
measured by Mancini's test or radioimmunoassay
(Mancini et al., 1965; Nishi & Hirai, 1976). Prior
to the conjugate therapy, the optimal effective dose
of DM to Li-7 growing in nude mice was deter-
mined. Nude mice inoculated with 106 cells of
Li-7 on day 0 were treated with PBS or 5, 10, or
20,pg of DM starting from day 14 at 5-day intervals
for a total of 4 times. On day 30, mice were killed
and RTS, body weight and serum AFP level were
measured.
The anti-AFP and control normal conjugates
were prepared by conjugation of DM with aAFP
and nIg with the use of a single thiol group-bearing
PLGA derivative as the intermediate drug carrier.
The DM-to-Ig binding ratios and other pertinent
chemical data of the conjugates prepared and
evaluated are shown in Table I.
The RTS on day 30 of nude mice injected with
PBS was 9.8, whereas those of nude mice treated
with 5, 10 or 20pg of DM were 7.2, 2.8 and 2.2,
respectively, which indicated 27, 72 and 78%
inhibition of tumour growth as shown in Table II.
Table I Chemical data on PLGA-DM and Ig-PLGA-
DM conjugatesa
Conjugate Anti-AFP Normal
PLGA-DM
Average mol. wt. of PLGAb 9900 9900
Degree ofpolymerization
of PLGA 65.6 65.6
DM-to-PLGA binding ratioc 6.8 6.8
Drug-substitution rate, %d 10.4 10.4
Ig-PLGA-DM
PLGA-to-Ig binding ratio' 2.43 2.24
DM-to-Ig binding ratiof 16.5 15.2
Purity,%9 82.3 84.9
aThe methods for quantitation of DM, the 2-
pyridyldithio group and Ig are the same as those
described in the previous paper (Tsukada et al., 1984).
bDetermined by the end-group (2-pyridyldithio) analysis
with respect to a lyophilized aliquot of Py-ss-PLGA.
cThe DM content (mol) was determined spectrophoto-
metrically, and the PLGA content by end-group analysis.
dThe average percentage of the DM-linked carboxyl
groups among the total number of the carboxyl groups in
PLGA.
eCalculated by division of the DM-to-Ig binding ratio
by the DM-to-PLGA binding ratio.
fThis number was obtained from mol of Ig in the
conjugate preparation (determined by the Bio-Rad protein
assay) and mol of Ig-linked DM as determined by
multiplication of the total DM content (Ig-linked DM
plus DM as PLGA-DM) of the conjugate preparation
(determined spectrophotometrically) by p/i00 [p=purity
(%) of the conjugate shown in this table].
gPurity denotes the percentage (p) of the Ig-linked DM
to the total amount of DM (Ig-linked DM plus DM as
PLGA-DM), determined as follows: The conjugate
preparation was subjected to disc PAGE: Ig-PLGA-DM
and PLGA-DM were isolated by electrophoresis of the
respective bands eluting out of the gel; and the amounts of
DM obtained in the two forms, Ig-PLGA-DM and
PLGA-DM were determined spectrophotometrically.
Serum AFP level corresponded well with the data
of RTS showing suppression of AFP levels
especially in groups of mice treated with 10 or
20pg DM. Body weights were measured as an
indicator of a toxic or side effect of DM on the
host. Some retardation in the increase of body
weight was observed in the groups of mice treated
with 5 or 104ug DM. Mice treated with 20pg DM
exhibited marked retardation in the increase of
body weight. These data indicate that the optimal
effective dose of DM against Li-7 under the
experimental conditions used is - 10pg per head.
Figure lA shows the RTS curves of the Li-7
tumour in nude mice treated with the conjugateANTI-HUMAN AFP ANTIBODY-DAUNORUBICIN CONJUGATE
Table II Optimal effective dose of daunorubicin to the Li-7 hepatoma cells
growing in nude mice
Dose RTSa Body
Treatment injection (day 30) weight (g) AFP (,Mgml 1)
PBS 0 9.8 38.5 402.4
daunorubicin 5 7.2 31.5 260.7
daunorubicin 10 2.8 30.0 97.8
daunorubicin 20 2.2 22.5 92.4
No. of mice 2, RTS: relative tumour size
aMice were killed 30 days after transplantation of Li-7 cells and optimal
effective dose of daunorubicin was determined from RTS, body weight and
serum AFP at day 50.
aAFP-PLGA-DM and various other test materials.
The RTS curves of mice treated with aAFP, DM,
aAFP plus DM, PLGA-DM, aAFP plus PLGA-
DM or Ig-PLGA-DM all showed similar moderate
inhibition of tumour growth, which is statistically
significant as compared with the inhibition in mice
injected with PBS by Student t-test (P<0.01) (RTS:
PBS, 12.26+0.15; 6 other test materials, 3.25+0.2-
4.14+0.06).
A striking suppression of tumour growth was
observed in the group of mice treated with a
AFP-PLGA-DM i.e. there was essentially no
proliferation of Li-7 and the inhibition of tumour
growth at day 49 was statistically significant
compared even with the RTS of the group of mice
treated with aAFP plus DM (P<0.05) (RTS: aAFP
plus DM, 3.25+0.2; aAFP-PLGA-DM, 1.14
±0.03).
No significant difference of rate of increase in
body weight was observed between the control PBS
group and the DM and aAFP-PLGA-DM groups
except slight reduction of body weight in the drug-
treated groups within one week after the initial
treatment (Figure iB).
Serum AFP levels were well correlated with the
growth of Li-7 as an indicator of cell proliferation.
A high AFP level ranging from 380 to 430pgml-1
was found in the groups of mice treated with PBS
(432+63) or nlg (381+61). Moderately elevated
levels of AFP were detected in the groups of mice
treated with DM (71+5.4), PLGA-DM (62+4.9)
or nlg-PLGA-DM (35+2.8). A low level of AFP
ranging from 13 to 67ngml-1 was observed in the
groups of mice treated with aAFP (13 + 1.2), aAFP
plus DM (53+4.4) or aAFP plus PLGA-DM (67
±5.9), although the RTS curves were almost the
same as those of mice treated with DM, PLGA-
DM or nlg-PLGA-DM. The group of mice treated
with aAFP-PLGA-DM showed an extremely low
level of AFP (2.2+0.18ngml-1), which was
estimated as the normal AFP level.
It has been demonstrated that antibodies to rat
AFP exhibit cytotoxicity to AFP-producing hepato-
cellular carcinoma cells in rat both in vitro and in
vivo (Tsukada et al., 1974: Wepsic et al., 1980). The
positive imaging by radioimmunodetection as well
as positive immunostaining of cell surface by
antibody to AFP indicates that the antibody
molecules localize to the tumour by coupling to the
cell surface-associated AFP molecules (Koji et al.,
1980; Tsukada et al., 1974). Recently, the targeting
chemotherapy by polyclonal or monoclonal anti-
bodies to tumour-associated antigens has been
extensively studied (Latif et al., 1980; Embleton et
al., 1981; 1983; Bernhard et al., 1983; Garnett et
al., 1983). Similar approaches have been made
utilizing purified antibody to rat AFP and anti-
cancer drugs such as daunorubicin (DM) and
mitomycin C (MMC) (Tsukada et al., 1982a; 1982b;
1983). Recently our-laboratory (Kato et al., 1983)
developed a new method of conjugation of DM
with antibody with a single thiol group-bearing
PLGA derivative as intermediate drug carrier and
the anti-rat AFP antibody-PLGA-DM conjugate
prepared by this method showed a potent anti-
tumour activity against the AFP-producing ascites
hepatocellular carcinoma cells AH66 growing in
DONRYU rats (Tsukada et al., 1984).
The antitumour activity of the present aAFP-
PLGA-DM conjugate prepared by the same new
method with the use of antibody to human AFP
was assessed in terms of the suppressive effect on
growth of the AFP-producing human tumour Li-7
in nude mice in comparison with various test
materials (Figure IA). The effect of the conjugate
was greater than those of all other test materials.
The maintenance of low AFP level in the group of
mice treated with aAFP, aAFP plus DM, and
aAFP plus PLGA-DM was probably caused by two
factors viz. the selective decrease of AFP high-
producing tumour cells and of remaining antibody
to AFP (Tsukada et al., 1974b; 1982a) (Figure 2).
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Figure 1 Therapeutic activity of anti-human AFP-PLGA-DM. Li-7 cells, 1-1.5 x 106 were transplanted into
nude mice on day 0. aAFP-PLGA-DM (aAFP 142 g, DM 10kg mouse/injection) and other test materials
were administered i.p. twice a week for a total of 8 times from day 17 to day 42 and RTS was determined at
the same time and on day 49. Average body weight of each group was determined by the same schedule as
that for the administration of the test materials. The average body weight on day 0 was 25.3 g. (0) aAFP-
PLGA-DM; (-) nlg-PLGA-DM; (*) aAFP plus PLGA-DM; (O) PLGA-DM; (x) aAFP plus DM; (--------)
DM; (0) aAFP; (El) nIg; ( ) PBS; (t) Li-7 1-1.5 x l0 cells, s.c.; (t) i.p. treatment.
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Figure 2 Serum AFP level at day 49. Mice were killed by cervical dislocation on day 49 and serum AFP
level was measured by Mancini's test or radioimmunoassay.
This is the first study ever reported to use the
system of antibody to human AFP: human AFP-
producing tumour with very encouraging results.
The utilization of monoclonal antibody to human
AFP for conjugation with DM may be possible
since a conjugate of DM with a monoclonal
antibody to rat AFP proved to be as effective as
the corresponding polyclonal antibody conjugate
(Tsukada et al, 1982b; 1983).
The overall conclusion from the present study is
that aAFP-PLGA-DM exhibits a potent anti-
tumour activity toward a human AFP-producing
neoplasm in nude mice by the homing effect of
antibody. The result should be regarded as bringing
the targeting of chemotherapy one step closer to
clinical trials.
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